Email us for help
Loading...
Premium support
Log Out
Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.
Dr. Ali is the primary investigator on a clinical trial to use a vaccine to extend remissions following successful myeloma treatment. The GVAX study is open for patients who are MRD positive but don't yet have a measurable m-protein. Dr. Ali explains how the vaccine works and why patients may want to use it to lengthen theri remission times.
Thanks to our episode sponsor, Bristol Myers Squibb.